

# Clinical trials of tenecteplase

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
<b>Eptifibatide + tenecteplase vs primary intervention</b>			
<a href="#">ADVANCE-MI , 2005</a> n=69/77 follow-up: 30 days	-	symptom duration <4h	
<b>tenecteplase vs accelerated t-PA</b>			
<a href="#">ASSENT-2 , 1999</a> n=8461/8488 follow-up: 30d	Tenecteplase en IV bolus (dose en fonction du poids: 30 mg si <60 kg; 35 mg si poids entre 60 et 69.9 kg; 40 mg pour les 80-89.9 kg; 50 mg si >ou = 90 kg versus Alteplase en IV, bolus de 15 mg, puis 0.75 mg/kg (sans dpasser 50 mg) en 30 min puis 0.50 mg/kg (sans dpasser 35 mg) en 60 min	patients with acute myocardial infarction of less than 6 h duration	Parallel groups double blind 29 countries
<b>tenecteplase vs primary intervention</b>			
<a href="#">GRACIA (Fernandez-Aviles) , 2004</a> n=104/108 follow-up: 30-day	facilitated PCI with bodyweight-adjusted intravenous tenecteplase bolus: 30 mg of drug if bodyweight <60 kg, 35 mg if 60-69 kg, 40 mg if 70-79 kg, 45 mg if 80-89 kg, and 50 mg if >=90 kg and Abciximab; 0.25 mg/kg intravenous bolus, 0.125 g/kg per min infusi versus primary intervention	symptom duration <12h	

More details and results :

- myocardial revascularization for acute myocardial infarction in facilitated PCI at <http://www.trialresultscenter.org/go-Q90>
- myocardial revascularization for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q129>
- fibrinolysis for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q260>

## References

### ADVANCE-MI, 2005:

Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADDRESSING the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. Am Heart J 2005;150:116-22 [16084157]

### ASSENT-2, 1999:

Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, Betriu A, Binbrek AS, Califf R, Diaz R, Fanebust R, Fox K, Granger C, Heikkil J, Husted S, Jansky P, Langer A, Lupi E, Maseri A, Meyer J, Mlczoch J, Mocceti D, Myburgh D, Oto A, Pao Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999 Aug 28;354:716-22 [10475182]

### GRACIA (Fernandez-Aviles, ), 2004:

Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al.pj Primary versus facilitated percutaneous coronary intervention (tenecteplase plus stenting) in patients with ST-elevated myocardial infarction: the final results of the GRACIA-2 randomized trial Eur Heart J 2004; 25 (suppl): 33 (abstrg

## 2 pulmonary embolism

Trial	Treatments	Patients	Trials design and methods
<b>tenecteplase vs placebo</b>			
PEITHO <i>ongoing</i> [NCT00639743] n=NA follow-up: 7 days	tenecteplase (single i.v. bolus) versus placebo	patients with sub-massive pulmonary embolism	Parallel groups double-blind

More details and results :

- fibrinolysis for pulmonary embolism in all type of patients at <http://www.trialresultscenter.org/go-Q110>

## References

### PEITHO, :

ongoing trial NCT00639743

Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J 2012;163:33-38.e1 [22172434] 10.1016/j.ahj.2011.10.003

## 3 cardiac arrest

Trial	Treatments	Patients	Trials design and methods
<b>tenecteplase vs placebo</b>			
<b>TROICA , 2008</b> [NCT00157261] n=525/525 follow-up: 30 days	tenecteplase (dose according to estimated body weight) versus placebo	adults with witnessed out-of-hospital cardiac arrest of presumed cardiac origin and with initiation of basic or advanced life support within 10 minutes after collapse	Parallel groups double blind Europe
<b>TICA , 2004</b> n=19/16 follow-up:	tenecteplase 50 mg versus placebo	All victims of out of hospital cardiac arrest	Parallel groups double blind Australia

More details and results :

- fibrinolysis for cardiac arrest in all type of patients at <http://www.trialresultscenter.org/go-Q239>

## References

### **TROICA, 2008:**

Bttiger BW, Arntz HR, Chamberlain DA, Bluhmki E, Belmans A, Danays T, Carli PA, Adgey JA, Bode C, Wenzel V Thrombolysis during Resuscitation for Out-of-Hospital Cardiac Arrest. N Engl J Med 2008 Dec 18;359:2651-2662 [19092151] [10.1056/NEJMoa070570](https://doi.org/10.1056/NEJMoa070570)

Sphr F, Arntz HR, Bluhmki E, Bode C, Carli P, Chamberlain D, Danays T, Poth J, Skamira C, Wenzel V, Bttiger BW International multicentre trial protocol to assess the efficacy and safety of tenecteplase during cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest: the Thrombolysis in Cardiac Arrest (TROICA) Study. Eur J Clin Invest 2005;35:315-23 [15860043]

### **TICA, 2004:**

Fatovich DM, Dobb GJ, Clugston RA A pilot randomised trial of thrombolysis in cardiac arrest (The TICA trial). Resuscitation 2004;61:309-13 [15172710]

Entry terms: tenecteplase, Metalyse, Boehringer Ingelheim brand of tenecteplase, TNKase, Hoffmann-La Roche brand of tenecteplase, Genentech brand of tenecteplase,